Stripe and AI Giants Pledge $500M to Kill the Common Cold Forever
Tech billionaires are finally focusing on a virus that actually matters to normal humans instead of just building another chatbot. This massive biological intervention might finally free us from the annual sniffle hell, if the corporate hype doesn't choke it first.
The payments giant Stripe kickstarted a non-profit initiative called Intercept, recruiting heavyweights like the OpenAI Foundation, Anthropic, and billionaire Bill Gates to pool resources. The coalition wants to completely eliminate respiratory infections, treating the common cold not as an inevitable annoyance but as a systems bug that needs a patch.
Instead of funding traditional medical academic circles, this venture capital style play targets two distinct fronts. First, they are looking for broad-spectrum nasal sprays and physical blockers that trap viruses before they can enter human cells. Second, they want to sanitize indoor air using ultraviolet light and advanced filtration systems, essentially treating shared office air with the same aggressive purification we apply to tap water.
This initiative mimics a model that Stripe previously deployed for carbon removal. Because traditional pharmaceutical giants prefer treating symptoms rather than preventing them—since healthy people are notoriously bad repeat customers—private tech money is stepping in to absorb the early-stage financial risks of drug development.
To keep things realistic, the fund is led by Nan Ransohoff and Charlie Petty from Stripe, advised by Peter Marks, a former high-ranking official at the FDA, and Moncef Slaoui, who ran the US vaccine initiative Operation Warp Speed. This is a deliberate attempt to employ operators who actually know how to navigate the bureaucratic labyrinth of drug approval rather than relying solely on laboratory dreamers.
While names like JP Morgan and Mastercard are listed as early testers, their current commitment is limited to trying out indoor air purifiers in their corporate offices. The actual fund size of half a billion dollars remains a drop in the bucket, considering that pushing a single experimental drug through early clinical trials routinely costs up to thirty million dollars.
It turns out that debugging the human body is vastly more expensive than debugging code, and tech money might finally be hitting its limits. If a coalition of the world's smartest AI minds and wealthiest payment processors cannot cure a simple runny nose, humanity might be doomed to sniffle through Zoom calls forever.
Source: MIT Technology Review
Comments
This is where the magic happens: AI reads your discussion and rewrites the article based on the most interesting comments. Each strong comment adds points to the meter below. Once the meter is full, the article updates live — no page reload needed.